How to Handle Activist Investors Post-Listing: Board Communication and Strategic Defence

The number of activist campaigns targeting Asia‑headquartered companies listed on US exchanges rose 37% year‑on‑year in 2025, according to data from Insightia, with Hong Kong and PRC issuers accounting for 22 of the 68 campaigns filed against non‑US companies on the NYSE and Nasdaq. This is not a cyclical blip. The combination of depressed valuations among small‑ to mid‑cap Chinese issuers, a more aggressive stance by US‑based hedge funds deploying Section 13(d) filings, and the SEC’s 2024 rule amendments shortening the Schedule 13D filing window from 10 days to five business days has created a structural shift. Boards of Hong Kong‑incorporated companies with a US listing now face a compressed timeline to identify, assess, and respond to an activist before the position is publicly known. The HKEX’s own 2025 consultation on enhanced board‑shareholder communication (HKEX Consultation Paper, March 2025) signals that Hong Kong regulators expect listed companies to have a documented engagement protocol. For CFOs and company secretaries of US‑listed Hong Kong issuers, the question is no longer whether an activist will appear, but whether the board has a pre‑agreed defence architecture that complies with both US proxy rules and Hong Kong corporate governance standards.

The Regulatory Asymmetry: US Filing Triggers vs. Hong Kong Board Duties

The five‑business‑day Schedule 13D filing deadline under the SEC’s 2024 amendments (effective 30 December 2024) means an activist acquiring 5% or more of a class of equity securities must disclose its position and intentions within five business days of crossing the threshold. For a Hong Kong‑incorporated company listed on Nasdaq, the board may learn of the activist’s existence only when the 13D is filed. This creates a regulatory asymmetry: the activist has already built its position and prepared its public narrative before the board can respond.

Hong Kong company law imposes a different set of obligations. Under Section 465 of the Companies Ordinance (Cap. 622), directors must exercise reasonable care, skill, and diligence. That duty extends to responding to a known activist campaign. The board cannot plead ignorance of the activist’s identity after the 13D filing. The SFC’s Code on Corporate Governance (CG Code, effective January 2024, provision A.2.7) states that the board should ensure effective communication with shareholders and that the company secretary should facilitate the flow of information between the board and management. A board that has no pre‑defined response protocol may breach its duty of care by failing to act promptly once the activist’s identity is known.

Practical implication: The board should pre‑authorise a response committee — typically the independent non‑executive directors (INEDs) plus the company secretary — that can convene within 24 hours of a 13D filing. The committee’s mandate should include authority to retain US proxy solicitation counsel and Hong Kong legal counsel without a full board vote, which can take 48–72 hours to schedule under most Hong Kong‑incorporated companies’ articles of association.

Section 13(d) Filing Mechanics for Hong Kong Issuers

A Hong Kong‑incorporated company with a US listing is a “foreign private issuer” (FPI) under SEC rules. FPIs are exempt from Section 14(a) proxy rules for certain shareholder proposals, but they are not exempt from Section 13(d) beneficial ownership reporting. The activist must file on Schedule 13D, not the shorter Schedule 13G available to passive investors. The five‑business‑day clock starts on the date the activist crosses the 5% threshold, not the date of settlement. T+1 settlement in the US market (effective May 2024) means the activist’s economic exposure is immediate, and the filing deadline is measured from trade date, not settlement date.

The board should instruct the company’s transfer agent and depositary bank (typically the DTC participant) to monitor for unusual accumulation patterns in the company’s ADR or ordinary share float. Most Hong Kong issuers list via ADR programmes; the depositary bank (e.g. BNY Mellon, JP Morgan) can flag a single beneficial owner accumulating more than 3% of the ADR float within a 30‑day window. This early‑warning system is not mandated by the HKEX or SEC but is standard practice among NYSE‑listed FPIs with a market capitalisation below USD 500 million.

Building the Board Communication Architecture Pre‑Campaign

The board’s response to an activist is only as fast as its communication channels. Most Hong Kong‑incorporated companies with a US listing have a board comprising Hong Kong‑resident INEDs, one or two PRC‑based executive directors, and possibly a US‑based director. Time‑zone differences alone can introduce a 12‑hour delay in decision‑making. The company secretary should maintain a secure, encrypted communication platform (e.g. Diligent Boards or a dedicated Signal group) that is tested quarterly with a simulated activist scenario.

The HKEX’s 2025 consultation on board‑shareholder communication (HKEX CP‑2025‑03, March 2025) proposes that listed companies disclose their shareholder engagement policy in the annual report. While this consultation is directed at HKEX Main Board and GEM issuers, US‑listed Hong Kong companies that also maintain a secondary listing on HKEX (a dual‑primary structure used by approximately 14 Hong Kong companies as of Q1 2025) will be directly affected. For those with a sole US listing, the HKEX guidance is not binding, but the SFC’s expectation of good corporate governance applies regardless of listing venue.

The Pre‑Approved Defence Playbook

A written defence playbook should cover four scenarios: (a) a 13D filing with a request for board seats; (b) a 13D filing with a public letter demanding a strategic review; (c) a proxy contest for the annual general meeting; and (d) a “vote no” campaign against director elections. Each scenario should specify:

Who speaks for the board (typically the chairman or lead INED)
The threshold for issuing a press release (within 48 hours of the 13D filing, per NYSE Listed Company Manual Section 202.05)
The process for engaging the activist directly (first meeting within 10 business days, with legal counsel present)
The escalation path if the activist refuses engagement (including preparation of a shareholder rights plan, or “poison pill”, under Section 314 of the Delaware General Corporation Law if the company is Delaware‑incorporated, or under Hong Kong law if the company is Hong Kong‑incorporated)

Hong Kong‑incorporated companies face a specific constraint: a shareholder rights plan must be approved by the board and, under certain circumstances, by shareholders under the Listing Rules. The HKEX’s position on poison pills for Hong Kong‑incorporated companies is that they are permissible but must not “frustrate” a bona fide offer without shareholder approval (HKEX Listing Rule 14.06B, which applies to notifiable transactions but is referenced by the SFC in its Takeovers Code guidance). A US‑style poison pill with a 10% trigger may violate the SFC’s Code on Takeovers and Mergers (Rule 2.2) if it prevents a mandatory general offer. Legal counsel should opine on the compatibility of any proposed pill with Hong Kong law before implementation.

Strategic Defence Tactics: Engagement, Disclosure, and Counter‑Narrative

Once the activist’s identity and demands are known, the board has three parallel workstreams: engagement, disclosure, and counter‑narrative. These run simultaneously, not sequentially.

Engagement begins with a formal letter from the chairman to the activist acknowledging receipt of the 13D and proposing a meeting within 10 business days. The SFC’s Code on Corporate Governance (CG Code, provision E.1.2) recommends that boards “maintain an ongoing dialogue with shareholders”. A refusal to meet without good reason may be cited by the activist as evidence of board entrenchment in subsequent proxy materials.

Disclosure obligations under US securities law require the company to file a Form 6‑K with the SEC within four business days of any material event, including the activist’s public demands. The 6‑K should include the board’s response, not merely the activist’s letter. The SEC’s 2020 guidance on the use of non‑GAAP financial measures in response to activists (SEC Compliance & Disclosure Interpretations, updated May 2023) warns against selectively disclosing adjusted metrics that paint a rosier picture than GAAP results. The board should instruct the audit committee to review any non‑GAAP figures included in the response.

The counter‑narrative is the board’s public statement of its strategy, performance, and capital allocation plans. This is where the company secretary plays a critical role in ensuring that the narrative is consistent with the company’s Hong Kong filings (e.g. the annual report filed with the Companies Registry under Section 662 of the Companies Ordinance) and the US filings (Form 20‑F). Any discrepancy between the two — for example, different revenue recognition policies under HKFRS vs. US GAAP — will be exploited by the activist.

The Poison Pill as a Deterrent, Not a Weapon

A poison pill should be viewed as a negotiating tool, not a permanent defence. The board can adopt a pill with a 15% trigger (the standard for US companies) and a one‑year sunset, subject to shareholder ratification at the next AGM. For Hong Kong‑incorporated companies, the pill must be structured as a rights issue under the company’s articles of association, which typically require board approval but not shareholder approval for the initial adoption. The SFC has not publicly opined on poison pills for Hong Kong‑incorporated US‑listed companies, but the HKEX’s 2024 guidance on anti‑takeover measures (HKEX Guidance Letter GL86‑16, updated December 2024) states that any measure that “materially restricts the ability of shareholders to exercise their voting rights” should be put to a shareholder vote.

Practical data point: Of the 12 activist campaigns against Hong Kong‑incorporated US‑listed companies between 2020 and 2024, only two resulted in the adoption of a poison pill (data from Lazard’s 2024 Activism Review). In both cases, the pill was withdrawn within six months after the activist agreed to a settlement. The pill’s value is as a deterrent to rapid accumulation, not as a weapon to block all engagement.

Proxy Contest Mechanics and Hong Kong AGM Timelines

If the activist proceeds to a proxy contest, the board must understand the interplay between US proxy rules and Hong Kong AGM mechanics. A Hong Kong‑incorporated company’s AGM must be held within 15 months of the previous AGM (Section 611 of the Companies Ordinance). The notice period is 21 clear days (Section 600). The activist can requisition a special resolution under Section 566, but the requisition must be signed by shareholders holding at least 5% of the voting rights. The activist, having filed a 13D, almost certainly meets this threshold.

The board can accelerate the AGM date to shorten the activist’s campaign window. This tactic — known as “advancing the meeting” — is permitted under Hong Kong law provided the notice period is met. The board should pre‑authorise a range of AGM dates in the playbook, with the company secretary holding a pre‑drafted notice of AGM that can be issued within 48 hours of the activist’s requisition.

Post‑Campaign Board Re‑evaluation: Governance, Composition, and Disclosure

After the activist campaign concludes — whether through settlement, proxy win, or board seat grant — the board must conduct a post‑mortem. The SFC’s Code on Corporate Governance (provision A.2.1) requires the board to review its own performance annually. A campaign is a stress test of that performance. The review should address:

Did the board have adequate time to respond? If not, the pre‑authorisation process needs revision.
Was the company’s valuation narrative credible? If the activist’s thesis resonated with institutional shareholders, the board should consider whether its strategy is properly communicated.
Were there any disclosure gaps between US and Hong Kong filings? If the activist identified a discrepancy, the audit committee should remediate it within the next 20‑F or annual return.

The board should also consider refreshing its composition. The HKEX’s 2025 consultation proposes that INEDs serving more than nine years be classified as non‑independent for certain purposes. A board that has had the same INEDs for a decade is more vulnerable to an activist’s argument that it lacks fresh perspectives. The company secretary should present a board succession plan to the nomination committee within 90 days of the campaign’s conclusion.

The Settlement Agreement: Key Terms for Hong Kong Issuers

If the board settles with the activist — typically by granting one or two board seats — the settlement agreement must be filed as a Form 6‑K with the SEC. The agreement should include a standstill provision of 12–24 months, during which the activist cannot acquire more than a specified percentage (usually 9.9%) of the company’s shares or launch another campaign. For Hong Kong‑incorporated companies, the standstill must be enforceable under Hong Kong law. A standstill that restricts the activist’s ability to sell shares may be void as a restraint on trade under common law principles. Legal counsel should draft the standstill as a voting agreement, not a share transfer restriction, to avoid this issue.

The settlement should also include a confidentiality clause covering board materials. The activist’s director designee will have access to non‑public information; the agreement should specify that the designee cannot share that information with the activist’s investment team. This is standard in US settlements but is often overlooked by Hong Kong‑incorporated companies, where the activist may be a Hong Kong‑based fund with close ties to the designee.

Actionable Takeaways

Pre‑authorise a board response committee with the power to retain US and Hong Kong counsel within 24 hours of a Schedule 13D filing, and test this protocol with a simulated activist scenario every quarter.
Instruct the ADR depositary bank to monitor for accumulation above 3% of float within a 30‑day window and report directly to the company secretary, not the CEO, to avoid conflicts of interest.
Ensure the annual report and Form 20‑F are reconciled for any material differences in financial reporting under HKFRS vs. US GAAP, as activists routinely exploit these discrepancies in public letters.
Draft a shareholder rights plan with a 15% trigger and one‑year sunset, and obtain a legal opinion on its compatibility with the SFC’s Takeovers Code before any activist appears.
Include a standstill provision of at least 12 months in any settlement agreement, structured as a voting agreement rather than a share transfer restriction, to ensure enforceability under Hong Kong law.